Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant TAG-72 (Minretumomab Biosimilar) antibody

This anti-TAG-72 (Minretumomab Biosimilar) antibody is a Humanized Monoclonal antibody detecting TAG-72 (Minretumomab Biosimilar) in FACS and in vivo. Suitable for Human.
Catalog No. ABIN7795096

Quick Overview for Recombinant TAG-72 (Minretumomab Biosimilar) antibody (ABIN7795096)

Target

TAG-72 (Minretumomab Biosimilar)

Antibody Type

Recombinant Antibody

Reactivity

Human

Host

  • 1
  • 1
Humanized

Clonality

  • 1
  • 1
Monoclonal

Conjugate

  • 2
This TAG-72 (Minretumomab Biosimilar) antibody is un-conjugated

Application

  • 2
  • 2
  • 2
  • 2
Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade

Research Grade
  • Expression System

    Mammalian cells

    Purpose

    Minretumomab Biosimilar, TAG-72 Monoclonal Antibody

    Characteristics

    Minretumomab Biosimilar uses the same protein sequences as the therapeutic antibody minretumomab. Minretumomab is a mouse monoclonal antibody that was designed for the treatment of cancers that express the TAG-72 antigen. This includes breast, colon, lung, and pancreatic cancers. A wide range of derivatives has been used in pharmaceutical research. Examples include chimeric and humanized minretumomab, as well as a fusion protein of a minretumomab single-chain variable fragment and the enzyme beta-lactamase.

    Purification

    Protein A or G affinity column

    Purity

    >95 % by reducing SDS-PAGE

    Endotoxin Level

    < 1 EU per 1 mg of the protein by the LAL method

    Immunogen

    Human TAG-72
  • Application Notes

    Optimal working dilution should be determined by the investigator.

    Restrictions

    For Research Use only
  • Format

    Liquid

    Concentration

    > 3 mg/mL

    Storage

    4 °C,-20 °C

    Storage Comment

    Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
  • Target

    TAG-72 (Minretumomab Biosimilar)

    Alternative Name

    Minretumomab Biosimilar

    Target Type

    Biosimilar
You are here:
Chat with us!